Michael Chuong, MD, discusses the study design of a trial evaluating radiation therapy in patients with locally advanced pancreatic cancer.
Michael Chuong, MD, medical director of proton therapy and photon therapy, radiation, Baptist Health South Florida, discusses the study design of a trial evaluating radiation therapy in patients with locally advanced pancreatic cancer.
The use of radiation therapy in this space is not a standard. However, a non-ablative dose can show promising efficacy with little adverse events.
According to Chuong, ablative radiation therapy in 5 fractions guided by MRIdian Linac online adaptive replanning or 15-25 fractions delivered with CT guidance can be viable options for this patient population.
0:08 | The study design is essentially a single-arm phase 2 trial in which all patients would have initially received chemotherapy before enrollment. Then if there was no evidence of distant progression, they would be considered for study participation.
0:24 | In the trial, all patients received 5 fractions or essentially 5 days of radiation therapy delivered on the meridian device, with the intent being to deliver an ablative, or very high dose to the tumor. This is a dose that is not routine or standard on regular radiation machines, just simply because the safety of that would be where it would not be safe to do.